Stephane De Botton

Villejuif, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 127 publications

Olutasidenib Alone or in Combination With Azacitidine as a Bridge to Transplant in Relapsed/Refractory mIDH1 AML.

Olutasidenib Alone or in Combination With Azacitidine as a Bridge to Transplant in Relapsed/Refractory mIDH1 AML.

Journal: European journal of haematology

Published: May 27, 2026

Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort.

Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort.

Journal: Leukemia

Published: April 14, 2026

Ultra-high-sensitivity next-generation sequencing-based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort.

Ultra-high-sensitivity next-generation sequencing-based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort.

Journal: Blood cancer journal

Published: March 11, 2026

Prognostic impact of intensive chemotherapy in patients with TP53-mutated AML.

Prognostic impact of intensive chemotherapy in patients with TP53-mutated AML.

Journal: Blood cancer journal

Published: March 10, 2026

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Journal: Blood

Published: January 20, 2026

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Journal: Blood

Published: January 20, 2026

Olutasidenib as maintenance therapy after treatment response in acute myeloid leukemia with persistent IDH1 mutation.

Olutasidenib as maintenance therapy after treatment response in acute myeloid leukemia with persistent IDH1 mutation.

Journal: Blood neoplasia

Published: January 12, 2026

Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid Leukemia.

Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid Leukemia.

Journal: Advances in therapy

Published: December 17, 2025

Genomic landscape of acute myeloid leukemia in adolescents and young adults.

Genomic landscape of acute myeloid leukemia in adolescents and young adults.

Journal: Leukemia

Published: December 11, 2025

CAR T cell-mediated bone marrow inflammation causes hematotoxicity and favors clonal hematopoiesis.

CAR T cell-mediated bone marrow inflammation causes hematotoxicity and favors clonal hematopoiesis.

Journal: Science translational medicine

Published: September 24, 2025

Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.

Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.

Journal: Leukemia

Published: August 25, 2025

Myelodysplastic syndrome with cryptic 5q deletions in young male patients showing sustained response to lenalidomide.

Myelodysplastic syndrome with cryptic 5q deletions in young male patients showing sustained response to lenalidomide.

Journal: Haematologica

Published: August 02, 2025

Showing 1-12 of 127

Last Updated: 09/26/2026